Claudio Fozza

Prof. Claudio Fozza

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2009 in Experimental Hematology
Verified
Journal Article
Closed access
CFClaudio Fozza
Claudio Fozza
SCSalvatore Contini
Salvatore Contini
AGAntonio Galleu
Antonio Galleu
MSMaria Pina Simula
Maria Pina Simula
PVPatrizia Virdis
Patrizia Virdis
MLMaurizio Longinotti
Maurizio Longinotti

20 March 2019 in Hematological Oncology
Verified
Journal Article
Open access
PDF file
GCGiovanni Caocci
Giovanni Caocci
OMOlga Mulas
Olga Mulas
EAElisabetta Abruzzese
Elisabetta Abruzzese
LLLuigiana Luciano
Luigiana Luciano
AIAlessandra Iurlo
Alessandra Iurlo
Massimo BrecciaMassimo Breccia
Massimo Breccia
Arterial occlusive events (AOEs) represent emerging complications in chronic myeloid leukemia (CML) patients treated with ponatinib. We identified 85 consecutive CML adult patients who were treated with ponatinib in 17 Italian centers. Patients were stratified according to the Systematic Coronary Risk Evaluation (SCORE) assessment, based on sex, age, smoking habits, systolic blood pressure, and total cholesterol levels.The 60‐month cumulative incidence rate of AOEs excluding hypertension was 25.7%. Hypertension was reported in 14.1% of patients. The median time of exposure to ponatinib was 28 months (range, 3‐69 months). Patients with a high to very high SCORE risk showed a significantly higher incidence rate of AOEs (74.3% vs 15.2%, P < 0.001). Patients aged ≥60 years showed a significantly higher incidence rate of AOEs (51.5% vs 16.9%, P = 0.008). In multivariate analysis, no association was found between AOEs and positive history of CV disease, age, dose of ponatinib, previous exposure to nilotinib, and comorbidities. Only the SCORE risk was confirmed as a significant predictive factor (P = 0.01; HR = 10.9; 95% C.I. = 1.7‐67.8). Patients aged ≥60 years who were treated with aspirin had a lower incidence rate of AOEs (33.3% vs 61.8%). Among the 14 reported AOEs, 78.6% of them showed grade 3 to 4 toxicity. This real‐life study confirmed the increased incidence of AOEs in CML patients treated with ponatinib, with high to very high SCORE risk. We suggest that patients aged ≥60 years who were treated with ponatinib should undergo prophylaxis with 100 mg/day of aspirin. Our findings emphasize personalized prevention strategies based on CV risk factors.

1 September 2015 in Leukemia Research
Verified
Journal Article
Closed access
CFClaudio Fozza
Claudio Fozza
GCGiovanna Corda
Giovanna Corda
FBFrancesca Barraqueddu
Francesca Barraqueddu
PVPatrizia Virdis
Patrizia Virdis
SCSalvatore Contini
Salvatore Contini
MLMaurizio Longinotti
Maurizio Longinotti

Verified
Journal Article
Open access
PDF file
FFFabio Forghieri
Fabio Forghieri
VNVincenzo Nasillo
Vincenzo Nasillo
APAmbra Paolini
Ambra Paolini
FBFrancesca Bettelli
Francesca Bettelli
VPValeria Pioli
Valeria Pioli
MLMario Luppi
Mario Luppi
Nucleophosmin (NPM1) gene mutations rarely occur in non-acute myeloid neoplasms (MNs) with <20% blasts. Among nearly 10,000 patients investigated so far, molecular analyses documented NPM1 mutations in around 2% of myelodysplastic syndrome (MDS) cases, mainly belonging to MDS with excess of blasts, and 3% of myelodysplastic/myeloproliferative neoplasm (MDS/MPN) cases, prevalently classified as chronic myelomonocytic leukemia. These uncommon malignancies are associated with an aggressive clinical course, relatively rapid progression to overt acute myeloid leukemia (AML) and poor survival outcomes, raising controversies on their classification as distinct clinico-pathologic entities. Furthermore, fit patients with NPM1-mutated MNs with <20% blasts could benefit most from upfront intensive chemotherapy for AML rather than from moderate intensity MDS-directed therapies, although no firm conclusion can currently be drawn on best therapeutic approaches, due to the limited available data, obtained from small and mainly retrospective series. Caution is also suggested in definitely diagnosing NPM1-mutated MNs with blast count <20%, since NPM1-mutated AML cases frequently present dysplastic features and multilineage bone marrow cells showing abnormal cytoplasmic NPM1 protein delocalization by immunohistochemical staining, therefore belonging to NPM1-mutated clone regardless of blast morphology. Further prospective studies are warranted to definitely assess whether NPM1 mutations may become sufficient to diagnose AML, irrespective of blast percentage.

1 November 2016 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
CFClaudio Fozza
Claudio Fozza
VCValeria Crobu
Valeria Crobu
MIMaria Antonia Isoni
Maria Antonia Isoni
FDFausto Dore
Fausto Dore

1 January 2017 in Journal of Immunological Methods
Verified
Journal Article
Closed access
CFClaudio Fozza
Claudio Fozza
FBFrancesca Barraqueddu
Francesca Barraqueddu
GCGiovanna Corda
Giovanna Corda
SCSalvatore Contini
Salvatore Contini
PVPatrizia Virdis
Patrizia Virdis
MLMaurizio Longinotti
Maurizio Longinotti